Aytu BioPharma is a specialty pharmaceutical company that commercializes branded prescription drugs for central nervous system conditions. Aytu does not develop drugs internally; it acquires or in-licenses approved treatments and sells them through third-party wholesalers, pharmacies, and its proprietary patient access platform, Aytu RxConnect. The company's lead product is EXXUA, an in-licensed treatment for major depressive disorder in adults, which Aytu markets through a dedicated sales force to psychiatrists and healthcare providers. Aytu also owns legacy, unpromoted product lines, including an ADHD portfolio of extended-release orally disintegrating tablets (Adzenys XR-ODT and Cotempla XR-ODT) and a pediatric allergy suspension (Karbinal ER). Aytu relies on contract manufacturers for drug production and generates revenue from prescription drug sales net of rebates, distribution fees, and co-pay assistance. Aytu uses the cash flows from its legacy ADHD and pediatric products to fund the commercial launch and adoption of EXXUA.